A comparative study of spinal cord compression management in metastatic prostate cancer: Teaching versus non-teaching hospitals in the United States.
non-teaching hospital
prostate cancer
radiation
spinal cord compression
surgery
teaching hospital
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
26 Dec 2023
26 Dec 2023
Historique:
revised:
04
12
2023
received:
11
10
2023
accepted:
10
12
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
26
12
2023
Statut:
aheadofprint
Résumé
Spinal cord compression (SCC) in metastatic prostate cancer (MPC) is a critical complication and multiple factors influence the optimal therapeutic strategy. We investigated the differences in practice patterns between teaching hospitals (TH) and non-teaching hospitals (NTH) across the United States. Using the National Inpatient Sample Database (NIS), we performed a retrospective study on hospitalizations with MPC and SCC between 2016 and 2020 in US. We compared demographic factors, comorbidities, treatment modalities, duration of hospitalization, financial expenditures, and mortality between TH and NTH. We also examined the patients' characteristics and outcomes in TH and NTH based on their chosen therapeutic strategy. We identified 11,380 admissions with metastatic prostate cancer and SCC; 9610 in TH and 1770 in NTH. The median cost of hospitalization was $21,922 in TH and $15,141 in NTH. Although the median age and Charlson comorbidity score did not differ between two groups, patients in TH were more likely to receive intervention (radiation or surgery) compared to NTH (Surgery: 28.2% in TH vs. 23.0% in NTH & Radiation: 12.1% in TH vs. 8.2% in NTH). Mortality was lower in TH than NTH (4.5% vs. 7.9%). In both TH and NTH, a higher proportion of patients with private insurance underwent surgery (TH: Surgery 25.1% vs. Radiation 18.8% & NTH: Surgery 27.0% vs. 6.9%). Black patients were more likely to receive radiation than surgery in TH (34.2% vs. 26.8%). This study showed a greater percentage of patients underwent surgical intervention at TH compared to NTH. Additionally, the type of insurance and racial background were associated with distinctive treatment approaches.
Sections du résumé
BACKGROUND
BACKGROUND
Spinal cord compression (SCC) in metastatic prostate cancer (MPC) is a critical complication and multiple factors influence the optimal therapeutic strategy. We investigated the differences in practice patterns between teaching hospitals (TH) and non-teaching hospitals (NTH) across the United States.
METHOD
METHODS
Using the National Inpatient Sample Database (NIS), we performed a retrospective study on hospitalizations with MPC and SCC between 2016 and 2020 in US. We compared demographic factors, comorbidities, treatment modalities, duration of hospitalization, financial expenditures, and mortality between TH and NTH. We also examined the patients' characteristics and outcomes in TH and NTH based on their chosen therapeutic strategy.
RESULTS
RESULTS
We identified 11,380 admissions with metastatic prostate cancer and SCC; 9610 in TH and 1770 in NTH. The median cost of hospitalization was $21,922 in TH and $15,141 in NTH. Although the median age and Charlson comorbidity score did not differ between two groups, patients in TH were more likely to receive intervention (radiation or surgery) compared to NTH (Surgery: 28.2% in TH vs. 23.0% in NTH & Radiation: 12.1% in TH vs. 8.2% in NTH). Mortality was lower in TH than NTH (4.5% vs. 7.9%). In both TH and NTH, a higher proportion of patients with private insurance underwent surgery (TH: Surgery 25.1% vs. Radiation 18.8% & NTH: Surgery 27.0% vs. 6.9%). Black patients were more likely to receive radiation than surgery in TH (34.2% vs. 26.8%).
CONCLUSION
CONCLUSIONS
This study showed a greater percentage of patients underwent surgical intervention at TH compared to NTH. Additionally, the type of insurance and racial background were associated with distinctive treatment approaches.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63-89. doi:10.14740/wjon1191
Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 Suppl):2371-2490. doi:10.1002/cncr.20408
Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev. 2001;23(1):72-81. doi:10.1093/oxfordjournals.epirev.a000798
Horný M, Yabroff KR, Filson CP, et al. The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance. Cancer. 2023;17:3252-3262. doi:10.1002/cncr.34905
Boopathi E, Birbe R, Shoyele SA, Den RB, Thangavel C. Bone health management in the continuum of prostate cancer disease. Cancers (Basel). 2022;14(17):4305. doi:10.3390/cancers14174305
Reginelli A, Patanè V, Urraro F, et al. Magnetic resonance imaging evaluation of bone metastases treated with radiotherapy in palliative intent: a multicenter prospective study on clinical and instrumental evaluation assessment concordance (MARTE study). Diagnostics. 2023;13(14):2334. doi:10.3390/diagnostics13142334
Urraro F, Nardone V, Reginelli A, et al. MRI radiomics in prostate cancer: a reliability study. Front Oncol. 2021;11:805137. doi:10.3389/fonc.2021.805137
So A, Chin J, Fleshner N, Saad F. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice. Can Urol Assoc J. 2012;6(6):465-470. doi:10.5489/cuaj.12149
Barlev A. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. JMCP. 2010;16(9):693-702. doi:10.18553/jmcp.2010.16.9.693
Management of Metastatic Spinal Cord Compression. Accessed August 29, 2023. https://sma.org/article/
Arrigoni F, Bruno F, Zugaro L, et al. Developments in the management of bone metastases with interventional radiology. Acta Biomed. 2018;89(Suppl 1):166-174. doi:10.23750/abm.v89i1-S.7020
Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the spine oncology study group. Spine (Phila Pa 1976). 2010;35(22):E1221-E1229. doi:10.1097/BRS.0b013e3181e16ae2
Wang S, Wang Y, Yu Z, et al. Surgical results and clinical risks of postoperative complications in patients with painful malignant spinal cord compression after decompressive surgery. J Pain Res. 2018;11:1679-1687. doi:10.2147/JPR.S162435
Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-648. doi:10.1016/S0140-6736(05)66954-1
Bledsoe TJ, Park HS, Rutter CE, Aneja S, Nguyen PL, Yu JB. Impact of health insurance status on prostate cancer treatment modality selection in the United States. Am J Clin Oncol. 2018;41(11):1062-1068. doi:10.1097/COC.0000000000000423
Tewari AK, Gold HT, Demers RY, et al. Effect of socioeconomic factors on long-term mortality in men with clinically localized prostate cancer. Urology. 2009;73(3):624-630. doi:10.1016/j.urology.2008.09.081
Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010;28(6):1069-1074. doi:10.1200/JCO.2009.26.2469
Williams VL, Awasthi S, Fink AK, et al. African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015. Cancer Med. 2018;7(5):2160-2171. doi:10.1002/cam4.1451
Lawson KA, Daignault K, Abouassaly R, et al. Hospital-level effects contribute to variations in prostate cancer quality of care. Eur Urol Oncol. 2021;4(3):494-497. doi:10.1016/j.euo.2020.08.010
HCUP-US NIS Overview. Agency for Healthcare Research and Quality. Accessed February 19, 2023. https://hcup-us.ahrq.gov/nisoverview.jsp
Barzilai O, Laufer I, Yamada Y, et al. Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: neurologic, oncologic, mechanicals stability, and systemic disease. JCO. 2017;35(21):2419-2427. doi:10.1200/JCO.2017.72.7362
Laufer I, Rubin DG, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist. 2013;18(6):744-751. doi:10.1634/theoncologist.2012-0293
Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of Clinimetric properties. Psychother Psychosom. 2022;91(1):8-35. doi:10.1159/000521288
Lenga P, Gülec G, Bajwa AA, et al. Emergency posterior decompression for metastatic spine tumors in octogenarians: clinical course and prognostic factors for functional outcomes. World Neurosurg. 2023;175:e1315-e1323. doi:10.1016/j.wneu.2023.04.125
Seal B, Sullivan SD, Ramsey S, et al. Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. Future Oncol. 2015;11(3):439-447. doi:10.2217/fon.14.242
Tangirala K, Appukkuttan S, Simmons S. Costs and healthcare resource utilization associated with hospital admissions of patients with metastatic or nonmetastatic prostate cancer. Am Health Drug Benefits. 2019;12(6):306-312.
Takvorian SU, Yasaitis L, Liu M, Lee DJ, Werner RM, Bekelman JE. Differences in cancer care expenditures and utilization for surgery by hospital type among patients with private insurance. JAMA Netw Open. 2021;4(8):e2119764. doi:10.1001/jamanetworkopen.2021.19764
Silber JH, Rosenbaum PR, Niknam BA, et al. Comparing outcomes and costs of medical patients treated at major teaching and non-teaching hospitals: a national matched analysis. J Gen Intern Med. 2020;35(3):743-752. doi:10.1007/s11606-019-05449-x
MacLean MA, Touchette CJ, Georgiopoulos M, et al. Systemic considerations for the surgical treatment of spinal metastatic disease: a scoping literature review. Lancet Oncol. 2022;23(7):e321-e333. doi:10.1016/S1470-2045(22)00126-7
Nemirovsky DR, Klose C, Wynne M, et al. Role of race and insurance status in prostate cancer diagnosis-to-treatment interval. Clin Genitourin Cancer. 2023;21(3):e198-e203. doi:10.1016/j.clgc.2022.12.009
Nabi J, Tully KH, Cole AP, et al. Access denied: the relationship between patient insurance status and access to high-volume hospitals. Cancer. 2021;127(4):577-585. doi:10.1002/cncr.33237
Harlan LC, Greene AL, Clegg LX, Mooney M, Stevens JL, Brown ML. Insurance status and the use of guideline therapy in the treatment of selected cancers. JCO. 2005;23(36):9079-9088. doi:10.1200/JCO.2004.00.1297
Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Trends in cancer survival by health insurance status in California from 1997 to 2014. JAMA Oncol. 2018;4(3):317-323. doi:10.1001/jamaoncol.2017.3846
Suh W, Master S, Liu L, Mills G, Shi R. The effect of payer status on survival of patients with prostate cancer. Cureus. 2021;13(2):e13329. doi:10.7759/cureus.13329